Petakh Tikva, Israel, March 11, 2022– (work wire) –Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), the biotechnology company that is developing a pipeline of small-molecule drugs that treat infections, cancer and liver disease, announced today that the company’s CEO, Dr. Hepatocellular carcinoma and cirrhosis at cannabinoid nanoconcentrations” at kanks The Medical Cannabis Conference in Tel Aviv to be held from 14-15 March 2022. The abstract will also be published in the peer-reviewed scientific journal Medical cannabis and cannabinoids. Can-Fite will hold 1×1 meetings with companies in the cannabis field regarding potential licensing and partnership opportunities.
Cannabis binds to CB1 and CB2 receptors that regulate the function of multiple organs and tissues of the body. Interestingly, cannabinoids also bind to the primary target of Can-Fite platform technology, the A3 adenosine receptor-associated Gi protein (A3AR) that is upregulated in inflammatory and tumor cells.
Can-Fite’s extensive body of research shows that A3AR agonists can eliminate inflammation and cancer through the specific induction of programmed cell death in these cells.
The results of the study will be presented at CannX and published in Medical cannabis and cannabinoids Highlighting the ability of CBD-rich T3/C15 at nanomolar concentrations to inhibit the growth of hepatocellular carcinoma and hepatocyte stellate cells by activating A3AR and downregulating the Wnt/β-catenin pathway.
Dr. Fishman stated, “These findings open a new therapeutic opportunity in hepatocellular carcinoma and fibrosis with small concentrations of cannabidiol (CBD) and low content of the psychotropic portion of THC.” Overexpression of the A3AR target including hepatocellular carcinoma.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical-stage drug development company with platform technology designed to handle multi-billion dollar markets in the treatment of cancer, liver and inflammatory diseases. The company’s lead candidate drug, Piclidenoson, is currently undergoing a phase 3 trial for psoriasis. Can-Fite’s liver drug, Namodenoson, is heading to a phase III trial of hepatocellular carcinoma (HCC), the most common form of liver cancer, and a phase IIb trial for the treatment of nonalcoholic steatohepatitis (NASH). Namodenoson has been granted orphan drug designation in the United States and Europe and fast-track designation as a second-line treatment for HCC by the US Food and Drug Administration. Namodenoson has also shown proof of concept for the potential treatment of other cancers including colon, prostate, and melanoma. CF602, the company’s third candidate drug, has been shown to be effective in treating erectile dysfunction. These drugs have an excellent safety profile with experience in more than 1500 patients in clinical studies to date. For more information, please visit the website: www.can-fite.com.
This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives make or may make forward-looking statements, either orally or in writing. Forward-looking statements may be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should,” “expect,” or other variations of these or other words. Similar words or by the fact that these statements do not relate strictly to historical or current issues. These forward-looking statements may be included in, without limitation, various filings that Can-Fite has made with the US Securities and Exchange Commission, press releases or oral statements made by or with the approval of an authorized executive of Can-Fite. officers. Forward-looking statements relate to events, activities, trends, or results that are expected or expected as of the date they are made.
Because forward-looking statements relate to matters that have not yet happened, these statements are inherently subject to risks and uncertainties that could cause Can-Fite’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite’s actual activities or results to differ materially from the activities and results projected in such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: our history of losses, the need for additional capital to fund our operations, and our inability to raise additional capital on acceptable terms, or at all; Uncertainty about cash flows and inability to meet working capital needs; impact of the COVID-19 pandemic; initiation, timing, progress, and results of our preclinical studies, clinical trials, and other product candidate development efforts;
Our ability to develop our product candidates in clinical trials or successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, timing of filings and other regulatory approvals; Clinical development, commercial marketing and market acceptance of our product candidates; Our ability to establish and maintain strategic partnerships and other forms of institutional collaboration; Implement our business model and strategic plans for our business and product candidates; the scope of protection we can establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; Competitors, technologies and our industry; Statements about the impact of the political and security situation in Israel on our business. and other risks and risk factors detailed in Can-Fite filings with the SEC and in periodic filings with TASE. In addition, Can-Fite operates in an industrial sector where the values of securities are highly volatile and may be affected by economic and other factors beyond its control. Can-Fite undertakes no obligation to publicly update these forward-looking statements, whether as a result of new information, future events, or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220311005040/ar/